Thymopentin is a type of immunostimulant drug. This drug stimulate or enhance the activity of the immune system by triggering off or increasing the functioning of one of its components. Thymopentin has immunomodulating properties and is a synthetic pentapeptide. It helps in the synthesis of thymic T cells, which are responsible for cell-mediated immunity. This drug is used for a patient with suppressed immunity to increase immunocompetence. It has a short plasma half-life of 30 seconds and is therefore available as an injectable. This is the subject of various clinical studies for the prevention and treatment of hepatocellular cancer and HIV infections.
The injection thymopentin market is anticipated to grow in the forecast period. As stated by World Health Organization, at the end of 2021, there were nearly 38.4 million HIV-positive patients globally. According to estimates, 0.7% of adults, between the ages of 15-49 are HIV positive. The prevalence of AIDS and the mortality rate associated with it may act as a driving force for the injection thymopentin market share. There is an increased demand for immunostimulants, which may help to fight such diseases. This can also be employed for the treatment of hepatocellular carcinoma, the most common type of liver cancer. Currently, several clinical trials and ongoing studies supporting the use of thymopentin injections for the treatment of hepatocellular cancer and HIV infections are in action, thus expanding the injection thymopentin market. The market for this may potentially be fueled by the increase in demand for downstream and single-use products. In the wake of the COVID-19 pandemic, there has been an increase in R&D activities which may create new opportunities for this market.
Although the injection thymopentin market is anticipated to expand in the coming years, there may be some challenges to the market. Thymopentin may be associated with a few side effects like nausea, fever, dizziness, chest distress, and minor adverse reactions in some cases. Alternate therapies, with fewer side effects, are available that may cause some hindrances in the growth of this market. Other than this, immunostimulants may be expensive due to their manufacturing process, thus not affordable for everyone. This may reduce the target population for thymopentin and therefore restrict the growth of the market.
There has been a hike in the R&D for thymopentin that is anticipated to provide lucrative opportunities for players to increase their market share in the injection thymopentin market. Numerous pharmaceuticals have started an initiative to discover newer trends that may benefit the people. Also, there has been rising health expenditure all over the global, chiefly in countries like the U.S., due to the prevalence of diseases of the immune system. This may also act as an opportunity to increase the market share of this market.
New product launches to flourish in the market
A study has been conducted at Liver Cancer Institute and Zhongshan Hospital, Fudan University, China to assess the efficacy of thymopentin for the prevention of the relapse and metastasis of hepatocellular cancer after excision. It was carried out for five years in a randomized allocation. Nearly 220 participants between the age groups of 18 Years to 75 Years took part in the study. This study produced a favorable result, with the primary outcome being disease-free survival for almost three years and the secondary outcome of overall survival for three years.
Segment Overview:
By application type: The injection thymopentin market is classified as tumors, hepatitis, and others. The tumor cases witnessed a sudden rise in the last few years. This has led to an urgent need for a potential treatment approach. The inflammation of the liver, caused by the hepatitis virus has infected nearly 354 million people globally. These viruses are of five types: namely A, B, C, D, and E. The use of thymopentin with antituberculosis drugs for the treatment of drug-resistant pulmonary tuberculosis is also under study.
By distribution channel: The injection thymopentin market is divided into retail pharmacy, online pharmacy, and others. In recent years, online pharmacies have become more popular. To avoid visiting a physical pharmacy, majority of people choose to obtain their drugs online. But these distribution channels have some disadvantages. There have been several cases of unregistered or unlicensed pharmacies dispensing inaccurate drugs. A retail pharmacy is an individual pharmacy or a set of pharmacies that is run by a pharmacist licensed by that particular state.
By end-users: The injection thymopentin market is categorized into hospitals, clinics, research institutes, and other. Since there is an increase in the prevalence of hepatocellular carcinoma and HIV cases, various research institutes are involved in the study of the efficacy of thymopentin for these diseases. In hospitals, thymopentin injections are mainly used to boost the immunity of an immunocompromised patient.
Competitive analysis and profiles of the major players in the injection thymopentin market, such as Active Peptide Company, Cisen pharmaceutical Co. ltd., Graton Pharma, Hainan Zhonghe Pharmaceutical Co. Ltd, Hybio Pharmaceutical Co. Ltd, Jiangsu Kingsley Pharmaceutical Co. Ltd, Santa cruz biotechnology, Shanghai Huayuan Pharmacy, Sinopharm A-Think Pharmaceutical Co., and Yangtze River Pharmaceutical Group are provided in this report. Merck KGaA is also one of the key market players in the injection thymopentin market
The injection thymopentin market is anticipated to grow in the forecast period. As stated by World Health Organization, at the end of 2021, there were nearly 38.4 million HIV-positive patients globally. According to estimates, 0.7% of adults, between the ages of 15-49 are HIV positive. The prevalence of AIDS and the mortality rate associated with it may act as a driving force for the injection thymopentin market share. There is an increased demand for immunostimulants, which may help to fight such diseases. This can also be employed for the treatment of hepatocellular carcinoma, the most common type of liver cancer. Currently, several clinical trials and ongoing studies supporting the use of thymopentin injections for the treatment of hepatocellular cancer and HIV infections are in action, thus expanding the injection thymopentin market. The market for this may potentially be fueled by the increase in demand for downstream and single-use products. In the wake of the COVID-19 pandemic, there has been an increase in R&D activities which may create new opportunities for this market.
Although the injection thymopentin market is anticipated to expand in the coming years, there may be some challenges to the market. Thymopentin may be associated with a few side effects like nausea, fever, dizziness, chest distress, and minor adverse reactions in some cases. Alternate therapies, with fewer side effects, are available that may cause some hindrances in the growth of this market. Other than this, immunostimulants may be expensive due to their manufacturing process, thus not affordable for everyone. This may reduce the target population for thymopentin and therefore restrict the growth of the market.
There has been a hike in the R&D for thymopentin that is anticipated to provide lucrative opportunities for players to increase their market share in the injection thymopentin market. Numerous pharmaceuticals have started an initiative to discover newer trends that may benefit the people. Also, there has been rising health expenditure all over the global, chiefly in countries like the U.S., due to the prevalence of diseases of the immune system. This may also act as an opportunity to increase the market share of this market.
New product launches to flourish in the market
A study has been conducted at Liver Cancer Institute and Zhongshan Hospital, Fudan University, China to assess the efficacy of thymopentin for the prevention of the relapse and metastasis of hepatocellular cancer after excision. It was carried out for five years in a randomized allocation. Nearly 220 participants between the age groups of 18 Years to 75 Years took part in the study. This study produced a favorable result, with the primary outcome being disease-free survival for almost three years and the secondary outcome of overall survival for three years.
Segment Overview:
By application type: The injection thymopentin market is classified as tumors, hepatitis, and others. The tumor cases witnessed a sudden rise in the last few years. This has led to an urgent need for a potential treatment approach. The inflammation of the liver, caused by the hepatitis virus has infected nearly 354 million people globally. These viruses are of five types: namely A, B, C, D, and E. The use of thymopentin with antituberculosis drugs for the treatment of drug-resistant pulmonary tuberculosis is also under study.
By distribution channel: The injection thymopentin market is divided into retail pharmacy, online pharmacy, and others. In recent years, online pharmacies have become more popular. To avoid visiting a physical pharmacy, majority of people choose to obtain their drugs online. But these distribution channels have some disadvantages. There have been several cases of unregistered or unlicensed pharmacies dispensing inaccurate drugs. A retail pharmacy is an individual pharmacy or a set of pharmacies that is run by a pharmacist licensed by that particular state.
By end-users: The injection thymopentin market is categorized into hospitals, clinics, research institutes, and other. Since there is an increase in the prevalence of hepatocellular carcinoma and HIV cases, various research institutes are involved in the study of the efficacy of thymopentin for these diseases. In hospitals, thymopentin injections are mainly used to boost the immunity of an immunocompromised patient.
Competitive analysis and profiles of the major players in the injection thymopentin market, such as Active Peptide Company, Cisen pharmaceutical Co. ltd., Graton Pharma, Hainan Zhonghe Pharmaceutical Co. Ltd, Hybio Pharmaceutical Co. Ltd, Jiangsu Kingsley Pharmaceutical Co. Ltd, Santa cruz biotechnology, Shanghai Huayuan Pharmacy, Sinopharm A-Think Pharmaceutical Co., and Yangtze River Pharmaceutical Group are provided in this report. Merck KGaA is also one of the key market players in the injection thymopentin market
Injection Thymopentin Market Report Highlights
| Aspects | Details |
 By Application |
|
 By Distribution Channel |
|
 By End-Users |
|
 By Region |
|
 Key Market Players | Hainan Zhonghe Pharmaceutical Co.,Ltd, Hybio Pharmaceutical Co.,Ltd, santa cruz biotechnology, Active Peptide Company, cisen pharmaceutical co., ltd., Graton Pharma, Shanghai Huayuan Pharmacy, Sinopharm A-Think Pharmaceutical Co., Yangtze River Pharmaceutical Group, Jiangsu Kingsley Pharmaceutical Co., Ltd |
 | Merck KGaA |
Loading Table Of Content...
